Health TrialsbyHealthPanel

Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients

ConditionsObstetric ComplicationGynecologic CancerLung DiseasesUltrasound
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorAin Shams University

About this trial

Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Any patient admitted to the obstetrics and gynecology intensive care unit

Disqualifiers

Patient's refusal

inability to do a lung ultrasound examination during the first 24 hours of admission

Trial population

critically ill women admitted in the ICU for any medical, obstetric, or surgical causes.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • ultrasound detection of any abnormal ultrasonographical findings.

    Diagnostic test

    ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress. While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 8-region technique will be used. The areas are four on each side of the chest. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left . Each region will be scored using the LUS aeration score. as follows: "0," A-pattern with 0-2 B-lines; "1," more than 2 separated B-lines; "2," multiple coalescent B-lines; or "3," lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 24. posterior region will be assessed if needed and if feasible. The venous status will be assessed through a subcostal view for inferior vena cava diameter.

Treatment groups

64 Participants
are divided into 2 treatment groups
Group A: obstetrics critically ill1 intervention
Group B: gynecological critically ill patients1 intervention

Trial outcomes

Primary outcomes

1

the Prevalence of different ultrasonographical abnormal lung signatures

presence or absence of us abnormalities as: abnormal sliding, interstitial syndrome, consolidation, cavitation, pleural effusion, or collapse

Time frame
From date of admission untill Death from any cause or discharge from ICU, whichever comes first. assessed up to 20 days

Secondary outcomes

1

correlation of ultrasonographic finding with mortality or poor outcome

frequency of occurrence of poor outcomes -mortality or ventilatory support- for every abnormal lung ultrasonographic signature.

Time frame
from the appearance of abnormal ultrasonographic signature to death or disharge from ICU which comes first , assessed up to 20 days from the day of admission
2

timing of appearance of abnormal ultrasonography lung signatures

the time of detection of the abnormal lung ultrasonographic finding

Time frame
on admission, after every 48 hours during ICU stay till death or dischrage from ICU which comes first, assessed up to 20 days from admission

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ain Shams University

Lead sponsor

Source ClinicalTrials.gov
Apply now